EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer

Heming Ge iD, Gerrit Wolters-Eisfeld, Thilo Hackert, Yuqiang Li, Cenap Güngör iD

PLOS One · 02.05.2025 · 20 (5) · e0322618

DOI: 10.1371/journal.pone.0322618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 02.05.2025. Verfasst von Heming Ge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Macrophages, Hypoxia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a low survival rate and limited responsiveness to current therapies. The role of hypoxia in the tumor microenvironment is critical, influencing tumor progression and therapy resistance. The aim of this study was to implement the complex dynamics of the hypoxic tumor microenvironment in PDAC in a hypoxia-related prognosis model.

Methods

We utilized single-cell RNA sequencing (scRNA-seq) data and integrated it with TCGA-PAAD database to identify hypoxia-responsive macrophage subsets and related genes. Kaplan-Meier survival analysis, Cox regression, and Lasso regression methods were employed to construct and validate a hypoxia-related prognostic model. The model’s effectiveness was evaluated through its predictive capabilities regarding chemotherapy sensitivity and overall survival.

Results

Our research integrated data from scRNA-seq and the TCGA-PAAD database to construct a hypoxia-related prognostic model that encompassed 13 critical genes. This hypoxia model independently predicted chemotherapy response and poor outcomes, outperforming traditional clinicopathologic features. Additionally, a pan-cancer analysis affirmed the relevance of our hypoxia-related genes across multiple malignancies, particularly highlighting KRTCAP2 as a pivotal biomarker associated with worse prognosis and reduced immune infiltration.

Conclusion

Our findings underscored the prognostic potential of hypoxia-related model and offered a novel avenue for therapeutic targeting, aiming to ameliorate outcomes in pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalMacrophagesHypoxiaHumansPrognosisSingle-Cell AnalysisTumor MicroenvironmentSequence Analysis, RNAFemaleMaleBiomarkers, TumorMiddle AgedGene Expression Regulation, NeoplasticKaplan-Meier Estimate

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.

ORCID-Profile: Heming Ge, Cenap Güngör

Zitieren

APA

Ge, H., Wolters-Eisfeld, G., Hackert, T., Li, Y., & Güngör, C. (2025). Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer. PLOS One, 20(5), e0322618. https://doi.org/10.1371/journal.pone.0322618

Vancouver

Ge H, Wolters-Eisfeld G, Hackert T, Li Y, Güngör C. Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer. PLOS One. 2025;20(5):e0322618. doi:10.1371/journal.pone.0322618

BibTeX
@article{Ge2025,
  author = {Ge, Heming and Wolters-Eisfeld, Gerrit and Hackert, Thilo and Li, Yuqiang and Güngör, Cenap},
  title = {Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {5},
  pages = {e0322618},
  doi = {10.1371/journal.pone.0322618}
}
Kostenlos starten →